ArticleEuropean journal of public health2026
Gender differences in adolescent anxiolytic, hypnotic and sedative use across 32 European countries: a multilevel analysis of the influence of country-level gender inequality and economic factors.
Article in European journal of public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Despite consistent evidence of higher anxiolytic, hypnotic, and sedative (AHS) use among adolescent girls, influence of country-level context in shaping gendered patterns remains unexplored. This study examines how national gender inequality and economic factors affect adolescent AHS use and its gender differences in Europe. We analysed cross-sectional data from 96 954 adolescents aged 15-16 across 32 European countries using the 2019 European School Survey Project on Alcohol and Other Drugs (ESPAD). Countries were grouped into tertiles according to the Gender Inequality Index (GII), GDP per capita and Gini index. We calculated lifetime AHS use prevalence and gender prevalence ratios (PRs). Multilevel logistic regressions estimated the contribution of country-level context to consumption variability, and the association of national inequalities and wealth with boys' and girls' consumption, adjusting for individual sociodemographic variables and AHS accessibility. Most countries showed significantly higher AHS use among girls. Countries with higher gender and income inequality and lower GDP per capita reported overall lower consumption and wider gender gaps (e.g. PRGII-Low = 1.18 [1.12-1.25], PRGII-High = 1.49 [1.40-1.59]). Country-level context accounted for 6.7% of between-country consumption variance. Significant interactions between country level context and gender were found, such that gender gaps were wider in countries with greater gender inequality (ORGII-Med*Girls = 1.16 [1.05-1.28], ORGII-High*Girls = 1.33 [1.19-1.48]), lower GDP per capita (ORGDP-Low*Girls = 1.25 [1.12-1.38]), and higher income inequality (ORGini-High*Girls = 1.19 [1.07-1.32]). Structural inequalities in gender and wealth were associated with adolescent AHS use across Europe. Focusing on cultural factors, medicalisation processes and their gendered impact could provide a meaningful framework for mental health interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.